Last reviewed 2026-04-23 · How we verify

Havrix Inj

Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children.

At a glance

Mechanism of action

Havrix contains inactivated (killed) hepatitis A virus antigen, which triggers both humoral and cellular immune responses without causing disease. The vaccine promotes the production of anti-HAV antibodies that provide protective immunity against hepatitis A infection. This protection typically develops within 2-4 weeks after vaccination and provides long-term immunity.

Approved indications

• Prevention of hepatitis A infection in adults and children

Common side effects

• Injection site soreness or swelling
• Headache
• Fatigue
• Fever
• Myalgia

Key clinical trials

• To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) (PHASE3)
• To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (PHASE3)
• To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Havrix Inj CI brief — competitive landscape report
• Havrix Inj updates RSS · CI watch RSS
• Boryung Pharmaceutical Co., Ltd portfolio CI